Case report: A case of pulmonary pleomorphic carcinoma treated with nivolumab that developed into pneumocystis pneumonia
Satoru Senooa Toshio Kubob Hirohisa Kanoa Kazuya Nishiia Masahiro Tabatab Katsuyuki Kiuraa
aDepartment of Allergy and Respiratory Medicine, Okayama University Hospital
bCenter for Clinical Oncology, Okayama University Hospital
A 40-year old man who had a mass in his right lung and abdominal cavity and lymphadenopathy of the mediastinum was diagnosed with pulmonary pleomorphic carcinoma (PPC). He received three regimens of chemotherapy; however, all of them led him to progression. He underwent nivolumab treatment as a fourth regimen. First, the tumor in his lung became bigger and then began shrinking. Three months after starting nivolumab, he was diagnosed with pneumocystis pneumonia (PCP). Nivolumab may be a good choice for PPCs; however, we should pay close attention to PCP during nivolumab therapy.
Pulmonary pleomorphic carcinoma Nivolumab Pneumocystis pneumonia Immune reconstruction inflammatory syndrome
Received 27 Dec 2016 / Accepted 28 Mar 2017
AJRS, 6(4): 283-286, 2017